National Institutes Of Health Awards $45.1M NINDS Grant For CNM-Au8 Study In ALS
Portfolio Pulse from Benzinga Newsdesk
Clene Inc. (NASDAQ:CLNN) has been awarded a $45.1 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to support an Expanded Access Protocol (EAP) for its investigational drug, CNM-Au8, in amyotrophic lateral sclerosis (ALS). The grant will fund a four-year study in collaboration with Columbia University and Synapticure. The EAP will allow ALS patients who don't meet the criteria for clinical trials to access CNM-Au8. Clene has shown evidence of consistent safety and improved survival for CNM-Au8 in two independent Phase 2 trials and an ongoing EAP.
October 05, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The $45.1 million grant from NINDS to Clene Inc. for its investigational drug, CNM-Au8, in ALS is a positive development. It not only provides financial support for the study but also validates the potential of CNM-Au8. This could boost investor confidence in the company.
The grant from NINDS is a significant financial boost for Clene Inc. and its investigational drug, CNM-Au8. It validates the potential of the drug and could lead to increased investor confidence in the company. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100